Randomized, Double-Blind, Placebo-Controlled Phase I/II Study of the Safety and Efficacy of Intracoronary Delivery of Allogeneic Cardiosphere-Derived Cells in Patients With a Myocardial Infarction and Ischemic Left Ventricular Dysfunction

Trial Profile

Randomized, Double-Blind, Placebo-Controlled Phase I/II Study of the Safety and Efficacy of Intracoronary Delivery of Allogeneic Cardiosphere-Derived Cells in Patients With a Myocardial Infarction and Ischemic Left Ventricular Dysfunction

Active, no longer recruiting
Phase of Trial: Phase I/II

Latest Information Update: 08 Nov 2017

At a glance

  • Drugs CAP-1002 (Primary)
  • Indications Left ventricular dysfunction; Myocardial infarction
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms ALLSTAR
  • Sponsors Capricor
  • Most Recent Events

    • 08 Nov 2017 According to a Capricor Therapeutics media release, results from this study will be presented at American Heart Association (AHA) Scientific Sessions on Nov 2017
    • 10 Aug 2017 According to a Capricor Therapeutics media release, six-month results from this study will be presented at a medical conference in the fourth quarter of 2017.
    • 12 May 2017 Results of interim analysis performed on six month follow-up data published in a Capricor Therapeutics Media Release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top